Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...

Brett Fishbin; Analyst; KeyBanc Capital Markets Inc. Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call ... reflecting the continuing demand for our AirSense 10 and AirSense 11 ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

CEO Michael Farrell reported 10% global revenue growth ... comfort and potentially redefining market standards for CPAP masks. ResMed also collaborated with Apple Vision Pro to introduce the ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability.

Its core business includes the development of devices for sleep apnea -- such as CPAP ... ResMed’s intention to provide integrated patient care solutions and expand its market reach. ResMed's 10 ...

The company's revenue for the period rose 10.3% to $1.282 billion from $1.162 billion last year. Resmed Inc earnings at a glance (GAAP) : -Earnings: $344.6 Mln. vs. $208.6 Mln. last year.

CSL Ltd (ASX: CSL) and ResMed Inc (ASX: RMD ... Robust Continuous Airway Pressure Therapy (CPAP) patient growth assisted by growing awareness on Obstructive Sleep Apnea (OSA), (2) Market share ...